步科股份(688160.SH):關注並佈局在醫療影像設備、物流與包裝等行業的發展
格隆匯7月30日丨步科股份(688160.SH)披露投資者關係活動記錄表顯示,除了重點關注機器人行業的發展外,公司還關注並佈局在醫療影像設備、物流與包裝等行業的發展。公司在醫療影像設備行業深耕多年,擁有與頭部國際品牌客户多年的合作經驗,具備深厚的行業積累,公司會持續在這個方向發力,保持已有的先發優勢。依託於公司在工業移動機器人(AGV/AMR)方向的領先優勢,公司將發展目光聚焦於物流、包裝等與移動機器人高度相關的應用場景中,為生產、包裝到產品出入庫等環節,提供從自動化包裝設備到物流出入庫的全場景解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.